Intact Peptide Bioanalysis and Exposure: Research Evidence 2026

What the measurements actually mean

ICH M10 (2022) treats accuracy, precision, selectivity, carryover, dilution integrity, stability, and incurred-sample reproducibility as separate validation questions. For a peptide, the assay may measure intact parent, total immunoreactive material, a metabolite, or a fragment. Reporting only a number in ng/mL without naming the species and matrix leaves the exposure claim underspecified.

Findings from peptide-relevant evidence

Tanaka and colleagues (2019) perfused 18 dipeptides through mouse brain for 2 minutes at 200 µM; Gly-Sar, Gly-Pro, and Tyr-Pro showed influx clearances of 7.60 ± 1.29, 3.49 ± 0.66, and 3.53 ± 0.74 µL/g·min, respectively (n=4). That measured range is evidence of transport in an in-situ model, not a human pharmacokinetic prediction. The study makes the operational implication clear: nominal time, flow, concentration, and sample identity must travel with the result.

For study teams, the useful record joins nominal and actual collection time, tube and processing conditions, freeze-thaw history, storage duration, calibration run, and below-quantification handling. Support staff can reconcile that chain and route discrepancies; bioanalytical and pharmacokinetic scientists own model selection and biological interpretation.

Evidence limits

The cited transport result is a short mouse perfusion experiment, not a dose-ranging or clinical exposure study. Validation guidance is general and does not establish a stability window for any particular peptide. A measured concentration should therefore be presented with species, units, period, population or sample count, method, and uncertainty.

Source register

The ten URLs above are the topic-specific register for this article. It combines ICH and FDA bioanalysis guidance, EMA guidance, clinical-trial quality guidance, and peptide transport literature; it is not a dosing recommendation.

Preserve the measured species

The Tanaka perfusion study measured 18 dipeptides during a two-minute mouse brain perfusion at 200 µM. Gly-Sar was 7.60 ± 1.29 µL/g·min, compared with 3.49 ± 0.66 for Gly-Pro and 3.53 ± 0.74 for Tyr-Pro, with n=4 for each result. These are influx-clearance measurements in a controlled in-situ model, not plasma AUC, human exposure, or proof of target engagement. Study design, time, flow, concentration, tissue, and assay identity must travel with the number.

ICH M10's separate questions for selectivity, accuracy, precision, stability, carryover, dilution integrity, and incurred-sample reproducibility matter because a clean calibration run does not prove specimen stability. A coordinator can reconcile collection timestamps, processing delay, freeze-thaw history, tube identity, storage duration, and below-quantification handling. Bioanalytical and pharmacokinetic scientists decide whether the signal represents intact parent, immunoreactivity, metabolite, or fragment.